Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06124807 · ClinicalTrials.gov registry record · Phase 2

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

A Phase 2 study of Obesity and Overweight and Obesity, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
179
Enrollment target
20
Study locations

NCT06124807: Completed Phase 2 study of Obesity and Overweight and Obesity, sponsored by Eli Lilly and Company.

NCT06124807 is a Phase 2 study of Obesity and Overweight and Obesity that has completed, run by Eli Lilly and Company. The registered enrollment target is 179 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06124807, a Phase 2 study of Obesity and Overweight and Obesity, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
179 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3305677 compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.

Primary Outcome

Least squares means were calculated using an MMRM model for post-baseline measures: Variable = Baseline\*Time + Strata\*Time + Treatment\*Time, where Treatment and Strata are factors. Variance-Covariance structure (Percent Change from Baseline) = Unstructured. Strata is defined by joint levels of Sex and Baseline BMI (\<=30, \>30 kg/m\^2).

Conditions Studied

Obesity Overweight and Obesity

Interventions

  • DRUG Placebo
  • DRUG LY3305677

Study Locations (20)

Florida

  • Northeast Research Institute (NERI) - Fleming Island
  • Suncoast Clinical Research, Inc. - New Port Richey
  • Charter Research - Winter Park - Orlando
  • Charter Research - Lady Lake - The Villages

Arizona

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa - Chandler
  • Headlands Research - Scottsdale - Scottsdale
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson - Tucson

California

  • Velocity Clinical Research, Huntington Park - Huntington Park
  • Peninsula Research Associates - Rolling Hills Estates
  • Diablo Clinical Research, Inc. - Walnut Creek

Illinois

  • Great Lakes Clinical Trials - Andersonville - Chicago
  • Great Lakes Clinical Trials - Ravenswood - Chicago

New York

  • Dent Neurologic Institute - Amherst
  • North Suffolk Neurology - Port Jefferson Station

Hawaii

  • Pacific Diabetes & Endocrine Center - Honolulu

Kansas

  • Cotton O'Neil Diabetes & Endocrinology - Topeka

Kentucky

  • L-MARC Research Center - Louisville

Trial Details

FieldValue
Enrollment Target 179 participants
Start Date 2023-11-17
Est. Completion 2025-07-09
Phase Phase 2
Eli Lilly and Company

1,341 total trials

What the finished NCT06124807 record still lists

NCT06124807 is an interventional study that assigns participants to a tested intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06124807 names 20 study sites across 11 states, led by Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT06124807 about?

NCT06124807 is a clinical study titled "A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight". The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3305677 compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.

What is the current status of trial NCT06124807?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2023-11-17. Estimated completion is 2025-07-09.

What conditions does trial NCT06124807 study?

This clinical trial studies the following conditions: Obesity, Overweight and Obesity.

What interventions are being tested in trial NCT06124807?

The interventions under investigation include: Placebo (DRUG), LY3305677 (DRUG).

Who is sponsoring clinical trial NCT06124807?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06124807 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06124807's enrollment target sits among peer trials

179 346th of 1053 higher than 708 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06581198 · 179 participants · Phase 2

    A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

  • NCT07356323 · 179 participants · NA

    A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06124807, the US trial registry maintained by the National Library of Medicine. NCT06124807 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.